Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
1.
Integr Cancer Ther ; 20: 15347354211002919, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33834863

RESUMO

OBJECTIVE: To provide higher level evidence on the benefits of a Chinese patent medicine (CPM) (Fufang E'jiao Syrup, FFEJS) for alleviating cancer-related fatigue (CRF), this article describes a protocol for a randomized controlled trial. METHODS/DESIGN: We designed a double-blind, placebo-controlled stratified permuted block randomization clinical trial on CRF among 3 types of cancer in China. Participants will be equally allocated to FFEJS group or placebo group according to the randomization sequence and the hospitals they were enrolled at. Each patient will receive 20 ml of either the study formula FFEJS or a placebo formula, 3 times a day for 6 weeks. The follow-up period will be another 4 weeks for safety evaluation. The primary outcome is the difference in improvement of fatigue as measured with the Revised Piper Fatigue Scale-Chinese Version (RPFS-CV). Secondary outcomes include change in fatigue (measured by routine blood panel and hormones in peripheral blood) and QoL (measured by Edmonton symptom assessment scale and Functional Assessment of Cancer Therapy). Patient safety will be measured by liver, renal or cardiac damage, and the risk of FFEJS having a tumor promotion and progression effect will be monitored throughout this study. Cost-effectiveness will also be evaluated mainly by incremental cost per each quality-adjusted life year gained. DISCUSSION: This article describes the study design of a CPM for CRF in patients with advanced cancer through exploring the effectiveness, safety, and cost-effectiveness of FFEJS. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04147312. Registered on 1 Sep 2019.


Assuntos
Medicamentos de Ervas Chinesas , Neoplasias , China , Análise Custo-Benefício , Método Duplo-Cego , Medicamentos de Ervas Chinesas/uso terapêutico , Fadiga/tratamento farmacológico , Fadiga/etiologia , Humanos , Estudos Multicêntricos como Assunto , Neoplasias/complicações , Neoplasias/tratamento farmacológico , Medicamentos sem Prescrição , Qualidade de Vida , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do Tratamento
2.
Allergy Asthma Immunol Res ; 13(2): 177-205, 2021 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-33474855

RESUMO

The prevalence of allergic diseases has increased dramatically in recent years in China, affecting the quality of life in 40% of the population. The identification of allergens is the key to the diagnosis of allergic diseases. Presently, several methods of allergy diagnostics are available in China, but they have not been standardized. Additionally, cross-sensitization and co-sensitization make allergy diagnostics even more complicated. Based on 4 aspects of allergic disease (mechanism, diagnosis procedures, allergen detection in vivo and in vitro as well as the distribution map of the most important airborne allergens in China) and by referring to the consensus of the European Society of Allergy and Clinical Immunology, the World Allergy Organization, and the important literature on allergy diagnostics in China in recent years, we drafted this consensus of allergy diagnostics with Chinese characteristics. It aims to standardize the diagnostic methods of allergens and provides a reference for health care givers. The current document was prepared by a panel of experts from the main stream of professional allergy associations in China.

3.
Immunotherapy ; 13(3): 227-239, 2021 02.
Artigo em Inglês | MEDLINE | ID: mdl-33317341

RESUMO

Aim: Multicenter study to investigate the safety of mite extract product Novo-Helisen Depot, Strengths 1 to 3 (NHD3), as subcutaneous immunotherapy (SCIT), in Chinese children and adolescents with allergic rhinitis (AR) and allergic asthma (AA). Patients & methods: We evaluated SCIT-related adverse events (AEs) during NHD3 14-week initial therapy in children (5-11 years) and adolescents (12-17 years) with perennial symptomatic AR and AA. Results: Among 3600 injections in 250 patients, 361/3600 (10.0%) injections caused SCIT-related AEs in 96/250 (38.4%) patients, 321/3600 injections (8.9%) caused local reactions in 89/250 (35.6%) and 40/3600 injections (1.1%) caused systemic reactions in 23/250 (9.2%). Conclusion: Initial SCIT treatment using NHD3 was safe and well tolerated in Chinese children and adolescents with AR and AA.

4.
Chin J Integr Med ; 26(4): 256-262, 2020 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-31970675

RESUMO

OBJECTIVE: To evaluate the effect of Chinese herbal medicine formula, modified Liujunzi Decoction (, MLJZT), for anorexia, utilized as adjunct therapy during chemotherapy treatment for patients with advanced non-small cell lung cancer (NSCLC). METHODS: The study adopted a propensity score-matched design based on a prospective database. From February 2016 to September 2017, patients with advanced NSCLC that received both cisplatin-based chemotherapy and MLJZT (IM group) were 1:1 propensity score-matched to patients that received the cisplatin-based chemotherapy alone (control group). Changes in anorexia and weight, as well as side effects were evaluated per week within 4-cycle chemotherapy. RESULTS: Overall, 156 patients with advanced NSCLC that had received chemotherapy from our database were identified and 53 pairs were matched successfully. In total, 48.6% (50/53) of patients in the IM group had anorexia-improvement compared to 28.3% (15/53) of patients in the control group, and a total of 39.6% (21/53) of patients in the control group had a worsening of anorexia compared to only 7.8% (8/53) of patients in the IM group (P<0.01). The weight reduced significantly over time in the control group (-2.36 ± 2.53 kg) as compared to the IM group (-0.62 ± 3.89 kg, P<0.01). CHM didn't reduce the efficacy of chemotherapy in shrinking tumor size, and didn't increase the incidence of side effects such as hematological and hepatorenal toxicity. CONCLUSION: MLJZT is effective and safe for alleviating anorexia in patients with NSCLC. These findings warrant the conduct of a randomized controlled trial.


Assuntos
Anorexia/tratamento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Medicamentos de Ervas Chinesas/uso terapêutico , Neoplasias Pulmonares/tratamento farmacológico , Anorexia/induzido quimicamente , Antineoplásicos/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Estudos de Casos e Controles , Cisplatino/administração & dosagem , Humanos , Manipulações Musculoesqueléticas , Pontuação de Propensão
6.
J Thorac Dis ; 9(11): 4607-4650, 2017 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-29268533

RESUMO

The present document is based on a consensus reached by a panel of experts from Chinese Society of Allergy (CSA) and Chinese Allergic Rhinitis Collaborative Research Group (C2AR2G). Allergen immunotherapy (AIT), has increasingly been used as a treatment for allergic rhinitis (AR) globally, as it has been shown to provide a long-term effect in improving nasal and ocular symptoms, reducing medication need, and improving quality of life. AIT is currently the only curative intervention that can potentially modify the immune system in individuals suffering from AR and prevent the development of new sensitization and the progression of disease from AR to asthma. Although the use of AIT is becoming more acceptable in China, to date no AR immunotherapy guideline from China is available for use by the international community. This document has thus been produced and covers the main aspects of AIT undertaken in China; including selection of patients for AIT, the allergen extracts available on the Chinese market, schedules and doses of allergen employed in different routes of AIT, assessment of effect and safety, patients' administration and follow-up, and management of adverse reactions. The Chinese guideline for AR immunotherapy will thus serve as a reference point by doctors, healthcare professionals and organizations involved in the AIT of AR in China. Moreover, this guideline will serve as a source of information for the international community on AIT treatment strategies employed in China.

7.
Chem Commun (Camb) ; 53(56): 7917-7920, 2017 Jul 11.
Artigo em Inglês | MEDLINE | ID: mdl-28654101

RESUMO

A new adenine-containing metal-organic framework (MOF), [Zn4O(adenine)4(benzene-1,3-dicarboxylate)4Zn2] (named as ZnBDCA), was synthesized solvothermally. ZnBDCA possesses high quantum yield (>50%) and nano-channels that can encapsulate acriflavine molecules to build a host-guest chemopalette for approaching white-light emission.

8.
Am J Rhinol Allergy ; 30(3): 201-8, 2016 May.
Artigo em Inglês | MEDLINE | ID: mdl-27216351

RESUMO

BACKGROUND: Real-world data of the subcutaneous immunotherapy (SCIT) with semi-depot house-dust mite (HDM) allergen extract (a HDM allergen extract that contains a 50%-50% mixture of Dermatophagoides pteronyssinus and Dermatophagoides farina) for allergic rhinitis and asthma was unavailable in China until recently. AIM: To investigate the effectiveness and safety of a HDM-SCIT for allergic rhinitis and asthma in Chinese patients. METHODS: A multicenter, single-arm, open-label, self-controlled study. Chinese patients with allergic rhinitis or allergic asthma and with a history of symptoms from HDM exposure were included and received allergen-specific immunotherapy for 1 year by subcutaneous injection of HDM-SCIT. The primary outcome measure was the percentage of patients with an improvement in symptom severity assessed at 12 months after initiation of the treatment. The occurrence of adverse events and compliance of treatment were also evaluated. RESULTS: A total of 272 outpatients were included for effectiveness analysis. The subject-evaluated improvement rate in the visual analog scale (VAS) was 76.1% and 71.3% at 6 and 12 months, respectively; corresponding values for investigator-evaluated VAS were 77.9% and 71.7%, respectively (p < 0.0001). Symptom score changes were -2.43 and -3.79 at 6 and 12 months, respectively (both p < 0.0001); the VAS improvement rate and symptom score change did not differ significantly between children and adolescents and/or adults. Good injection schedule adherence was found in 98.8% of the patients. No study drug-related serious adverse events or serious systemic allergic reactions occurred. CONCLUSION: HDM-SCIT was safe and effective in the treatment of allergic rhinitis and asthma in a Chinese population, with good compliance.


Assuntos
Antígenos de Dermatophagoides/uso terapêutico , Asma/terapia , Dessensibilização Imunológica , Rinite Alérgica/terapia , Adolescente , Adulto , Animais , Asma/imunologia , Criança , Pré-Escolar , China , Dermatophagoides pteronyssinus/imunologia , Feminino , Seguimentos , Humanos , Injeções Subcutâneas , Masculino , Pessoa de Meia-Idade , Rinite Alérgica/imunologia , Adulto Jovem
9.
Biomed Res Int ; 2015: 187620, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26000283

RESUMO

AIM: To investigate differences in the efficacy of sublingual immunotherapy with Dermatophagoides farinae drops in monosensitized and polysensitized allergic rhinitis patients. METHODS: The patients enrolled in the study were treated for more than one year by sublingual immunotherapy (SLIT) using Dermatophagoides farinae drops and were divided into a monosensitized group (n = 20) and a polysensitized group (n = 30). Total nasal symptom scores of patients before and after SLIT were analyzed to evaluate the curative effect. The phylogenetic tree of dust mite allergens as well as other allergens that were tested by skin prick test was constructed to help the analysis. RESULTS: There was no significant difference in the efficacy of SLIT between dust mite monosensitized and polysensitized patients. CONCLUSIONS: Both dust mite monosensitized and polysensitized patients could be cured by SLIT using Dermatophagoides farinae drops. This study provides a reference for the selection of allergens to be used in immunotherapy for polysensitized AR patients.


Assuntos
Antígenos de Dermatophagoides/imunologia , Dermatophagoides farinae/imunologia , Imunização , Rinite Alérgica/imunologia , Rinite Alérgica/terapia , Imunoterapia Sublingual , Animais , Reações Cruzadas/imunologia , Relação Dose-Resposta Imunológica , Humanos , Filogenia , Testes Cutâneos , Resultado do Tratamento
10.
Protein Expr Purif ; 109: 93-8, 2015 May.
Artigo em Inglês | MEDLINE | ID: mdl-25462803

RESUMO

House dust mite (Dermatophagoides farinae) allergen Der f1 is one of the most important indoor allergens associated with asthma, eczema and allergic rhinitis in humans. Therefore, sufficient quantities of Der f1 cysteine protease to be used for both experimental and therapeutic purposes are very much needed. Using recombinant DNA technology, high expression rates of cysteine proteases were obtained. The cDNA sequence encoding pro-Der f1 was cloned and expressed in Escherichia coli using the T7 based expression vector pET-44a and induced by isopropyl-ß-d-thiogalactoside at a final concentration of 0.2mM. Recombinant pro-Der f1 (pro-rDer f1) was expressed as an inclusion body and the isolated protease was solubilized, refolded and purified. The protease activities and IgE reactivities of pro-rDer f1 that were refolded by size-exclusion chromatography (SEC) were higher than those obtained by dilution. The pair of pro-rDer f1 polypeptides produced by this method could be used for more effective and safer allergen-specific immunotherapy or to produce enzymatically and immunologically active Der f1 for diagnostic testing and deciphering of immunotherapy mechanisms.


Assuntos
Alérgenos/metabolismo , Antígenos de Dermatophagoides/metabolismo , Proteínas de Artrópodes/metabolismo , Cisteína Endopeptidases/metabolismo , Escherichia coli/metabolismo , Expressão Gênica , Corpos de Inclusão/metabolismo , Redobramento de Proteína , Pyroglyphidae/metabolismo , Animais , Western Blotting , Cromatografia em Gel , Eletroforese em Gel de Poliacrilamida , Dissulfeto de Glutationa/metabolismo , Humanos , Imunoglobulina E/sangue , Peptídeo Hidrolases/metabolismo
11.
Mediators Inflamm ; 2014: 291618, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24778467

RESUMO

Vast amounts of allergen sequence data have been accumulated, thus complicating the identification of specific allergenic proteins when performing diagnostic allergy tests and immunotherapy. This study aims to rank the importance/potency of the allergens so as to logically reduce the number of allergens and/or allergenic sources. Meta-analysis of 62 allergenic sources used for intradermal testing on 3,335 allergic patients demonstrated that in southern China, mite, sesame, spiny amaranth, Pseudomonas aeruginosa, and house dust account for 88.0% to 100% of the observed positive reactions to the 62 types of allergenic sources tested. The Kolmogorov-Smironov Test results of the website-obtained allergen data and allergen family featured peptides suggested that allergen research in laboratories worldwide has been conducted in parallel on many of the same species. The major allergens were reduced to 21 representative allergens, which were further divided into seven structural classes, each of which contains similar structural components. This study therefore has condensed numerous allergenic sources and major allergens into fewer major representative ones, thus allowing for the use of a smaller number of allergens when conducting comprehensive allergen testing and immunotherapy treatments.


Assuntos
Alérgenos/química , Alérgenos/imunologia , Alergia e Imunologia/normas , Animais , China , Poeira , Humanos , Hipersensibilidade/imunologia , Imunoglobulina E/imunologia , Imunoterapia , Funções Verossimilhança , Ácaros , Conformação Molecular , Peptídeos/química , Filogenia
12.
Eye Sci ; 29(3): 151-4, 2014 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26011970

RESUMO

PURPOSE: To investigate the genotyping of Foxp3-3279 (A/Crs376158) genes in patients with dust mite-induced allergic conjunctivitis from Guangdong province and to explore the association between these genes and the susceptibility to dust mite allergic conjunctivitis. METHODS: In total, 80 patients with dust mite allergic conjunctivitis and 103 healthy Han Chinese were enrolled in the study and received genotyping of Foxp3-3279 (A/C,rs376158) by PCR-SSP technique. RESULTS: Genotype frequency of Foxp3-3279 AA, CA, and CC in patients with dust mite allergic conjunctivitis were 1.25%, 25.00% and 73.75%,respectively. Gene frequency of C and A in patients with dust mite allergic conjunctivitis were 86.25% and 13.75% with no significant difference from healthy counterparts (both P > 0.05). CONCLUSION: Foxp3-3279 polymorphisms did not significantly differ between patients with dust mite allergic conjunctivitis and healthy controls, implying that this genetic locus is probably not an independent risk factor of the underlying pathogenesis of dust mite allergic conjunctivitis.


Assuntos
Conjuntivite Alérgica/genética , Poeira , Fatores de Transcrição Forkhead/genética , Polimorfismo Genético , Pyroglyphidae , Animais , Estudos de Casos e Controles , Feminino , Frequência do Gene , Predisposição Genética para Doença , Genótipo , Humanos , Masculino
13.
Lin Chuang Er Bi Yan Hou Ke Za Zhi ; 17(8): 451-3, 2003 Aug.
Artigo em Chinês | MEDLINE | ID: mdl-14577252

RESUMO

OBJECTIVE: To explore the operative approach for nasosinus tumors involving the base of the anterior cranial fossa. METHOD: Seven cases with defects, diameter less than 2 cm, on the skull base without damage of the duramater were not repaired. Other 7 cases with defects, diameter more than 2.5 cm, on both the skull base and duramater were covered with frontalis muscle flap or temporalis fascia flap. RESULT: Following up 1-8 year. 6 of the 11 malignant tumors survived after 3 years and 2 cases did after 4 years; 3 cases of benignant tumors are still alive, neither meningoephalocele nor cerebrospinal fluid fistula and extracranial or intracranial infection occurred. CONCLUSION: This operative mode is closer to the tumor and easy to repair duramater and stop bleeding, and has fine exposure of every nasal sinus, minimal retraction of the frontal lobe. If diameter of defect is more than 2 cm on the skull base, the reconstruction is necessary.


Assuntos
Fossa Craniana Anterior , Neoplasias Nasais/cirurgia , Neoplasias da Base do Crânio/cirurgia , Adolescente , Adulto , Idoso , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Invasividade Neoplásica , Neoplasias Nasais/patologia , Neoplasias da Base do Crânio/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...